ArticleResearch and practice in thrombosis and haemostasis2026
Total thrombus formation system exploration of primary hemostasis in cirrhotic patients.
Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06050993 (Exploration of Primary Haemostasis in Cirrhotic Patients With T-TAS System and Effects of Platelets Mimicking Nanoparticles), which is not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Exploration of Primary Haemostasis in Cirrhotic Patients With T-TAS System and Effects of Platelets Mimicking Nanoparticles
Who cites it
3 citing papers in PubMed.
- An Automated Microfluidic System for Haemostasis Assessment in Cirrhosis With Thrombocytopenia.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Assessing primary hemostasis in cirrhosis: not only platelet count.Research and practice in thrombosis and haemostasis · 2026Article
- Clinical and pathophysiological perspectives on haemostasis, inflammation, and thrombo-haemorrhagic risk in cirrhosis.EXCLI journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary hemostasis is impaired in cirrhosis, characterized by thrombocytopenia, platelet dysfunction, elevated von Willebrand Factor (VWF) levels, and reduced a disintegrin-like metalloproteinase with thrombospondin type-1 motifs 13 (ADAMTS13) activity. Current clinical hemostasis tests assess biological parameters individually or use static clot formation models. Objectives: We aimed to study thrombus formation in patients with cirrhosis in whole blood under flow conditions with the Total Thrombus Formation Analysis System (T-TAS 01). We also investigated whether synthetic platelet-mimicking nanoparticles (PMNPs) could improve primary hemostatic function in cirrhotic samples. Methods: This observational study included 60 participants (30 patients with cirrhosis and 30 controls). All patients underwent blood cell counts, VWF profiling (antigen, activity, propeptide levels, and multimer analysis), ADAMTS13 activity measurement, and T-TAS 01 analysis using collagen-coated PL chips. In cirrhotic samples, T-TAS 01 assays were also performed after adding PMNPs to evaluate their hemostatic efficacy. Results: Patients with cirrhosis had significantly lower platelet counts (97 vs 218 G/L, Conclusion: T-TAS 01 effectively detects hemostatic impairment in patients with cirrhosis, which apparently is not compensated by the presence of elevated VWF levels. This approach may therefore serve as a valuable tool for assessing clinical and biological monitoring in patients with cirrhosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.